Free Fraction Calculation (Plasma) Calculator
Estimate unbound (free) drug fraction in plasma, free concentration, and protein-bound percentage for clinical pharmacology and therapeutic drug monitoring workflows.
Choose how your lab or study data are available.
Results
Enter your values and click Calculate Free Fraction.
Expert Guide to Free Fraction Calculation in Plasma
Free fraction calculation in plasma is one of the most practical and clinically meaningful concepts in pharmacokinetics. When a drug enters blood, it usually exists in two pools: a protein-bound portion and an unbound portion. The unbound pool, often called the free concentration, is generally the fraction that can cross membranes, interact with receptors, be filtered by the kidney, and produce pharmacologic activity. That is why clinicians, researchers, and pharmacometricians care deeply about free fraction. A total drug level may look normal while free exposure is actually elevated or reduced in a patient with altered protein status, organ dysfunction, inflammation, or drug-drug interactions.
The most common mathematical definition is simple: free fraction (fu) = free concentration / total concentration. Bound fraction is then 1 – fu, and bound percentage is (1 – fu) x 100. If bound percentage is already known, you can derive fu directly as fu = 1 – (bound% / 100). These equations are straightforward, but interpretation requires context. Plasma protein composition, assay method, sample handling, and patient factors can all influence your final number.
Why free fraction matters more than total concentration in many scenarios
Total concentration combines both active and inactive circulating pools. For drugs with high protein binding, tiny shifts in binding can produce large relative changes in free exposure. For example, if a drug is 99% bound (fu = 0.01), a shift to 98% bound doubles free fraction (fu = 0.02), which can meaningfully alter efficacy and toxicity risk, especially for narrow therapeutic index agents.
- Clinical toxicity assessment: Free concentration often tracks adverse effects better than total level when protein binding is unstable.
- Dose individualization: Critical care, renal failure, liver disease, and hypoalbuminemia can alter free levels at a given total concentration.
- Drug development: Free concentration drives pharmacodynamic modeling, receptor occupancy assumptions, and exposure-response analyses.
- Drug interaction evaluation: Binding displacement and protein changes can modify free fraction even when total concentration appears unchanged.
Core equations used in free fraction plasma calculations
- fu from measured values: fu = Cfree / Ctotal
- Bound fraction: fb = 1 – fu
- Bound percentage: Bound% = fb x 100
- Free concentration from total and bound%: Cfree = Ctotal x (1 – Bound%/100)
In practical reporting, it is useful to include all four outputs: fu, free concentration, bound fraction, and bound percentage. This improves clarity for clinicians and allows cross-checking between laboratory and pharmacokinetic teams.
Physiologic background: major plasma proteins and expected ranges
Plasma proteins are not interchangeable. Different drugs preferentially bind albumin, alpha-1-acid glycoprotein (AAG), lipoproteins, or combinations of these proteins. Albumin is the dominant plasma protein by concentration and is a key binder of many acidic and neutral compounds. AAG, though much lower in concentration, can strongly influence the free fraction of basic drugs and rises during inflammation, trauma, cancer, and acute stress.
| Parameter | Typical Adult Reference | Clinical Relevance to Free Fraction |
|---|---|---|
| Serum albumin | 3.5-5.0 g/dL (35-50 g/L) | Lower albumin can increase free fraction for highly albumin-bound drugs. |
| Alpha-1-acid glycoprotein (AAG) | Approximately 0.5-1.2 g/L | Inflammation can increase AAG, reducing free fraction of many basic drugs. |
| Plasma protein binding threshold often considered high | >90% bound | Small absolute changes in binding may create large relative shifts in free exposure. |
| Plasma water fraction | Approximately 90-92% of plasma volume | Only unbound drug in aqueous phase is immediately available for distribution and elimination. |
Examples of free fraction by drug class
Drug-specific protein binding can vary by population, assay, and concentration. Still, typical ranges provide useful orientation for calculator inputs and interpretation.
| Drug (Example) | Approximate Protein Binding | Approximate Free Fraction (fu) | Interpretive Note |
|---|---|---|---|
| Warfarin | ~99% | ~0.01 | Very high binding; small binding shifts can be clinically important. |
| Phenytoin | ~90% | ~0.10 | Free monitoring is valuable in hypoalbuminemia and renal dysfunction. |
| Valproic acid | ~85-95% (concentration dependent) | ~0.05-0.15 | Binding may become nonlinear at higher concentrations. |
| Theophylline | ~40% | ~0.60 | Moderate binding; total levels often closer to free behavior than highly bound drugs. |
| Gentamicin | <10% | >0.90 | Low binding; total concentration often approximates active exposure. |
How to use this calculator correctly
- Choose your mode: either direct measured free concentration or known bound percentage.
- Enter total concentration in your chosen unit.
- Enter either measured free concentration or bound percentage depending on mode.
- Optionally add a therapeutic free range to get a simple status interpretation.
- Click Calculate to obtain fu, bound fraction, free concentration, and bound percentage.
The chart visualizes the relationship between free and bound portions. For highly protein-bound drugs, expect a small free segment and a dominant bound segment. This visual cue can quickly communicate why free-level monitoring may be more informative than total concentration alone.
Common pitfalls in free fraction interpretation
- Assuming binding is constant: Critical illness, pregnancy, liver disease, nephrotic conditions, burns, and inflammation can alter binding proteins.
- Ignoring assay methodology: Ultrafiltration, equilibrium dialysis, and ultracentrifugation can produce slightly different free level estimates.
- Not accounting for timing: Peak versus trough and post-dose timing may change measured concentration relationships.
- Using population averages for individuals: Estimated fu is useful, but direct free measurement is best when clinical stakes are high.
- Forgetting concentration-dependent binding: Some compounds display nonlinear protein binding at therapeutic or supratherapeutic ranges.
Clinical contexts where free fraction monitoring is especially useful
Free fraction assessment is especially valuable for drugs with high binding and narrow safety windows. In neurology, free antiseizure drug concentrations can improve dosing in patients with low albumin. In intensive care, rapidly changing physiology can invalidate static binding assumptions. In hepatology and nephrology, altered protein synthesis, uremic toxins, and fluid shifts may increase discordance between total and free levels.
Drug development teams also rely on free fraction for translational modeling. In vitro potency, receptor occupancy targets, and preclinical-to-clinical scaling are generally interpreted through unbound concentrations. Regulatory submissions routinely discuss plasma protein binding and unbound exposure because free drug is central to pharmacologic relevance.
Quality checks for better calculations
- Verify that free concentration is not greater than total concentration.
- Confirm unit consistency before interpreting results.
- Document patient albumin and major inflammatory markers when possible.
- Repeat measurement if results conflict with clear clinical signs.
- Use the same sample handling method across serial monitoring points.
Interpreting trends over time
A single free fraction is informative, but a trend is often more powerful. Rising free fraction at stable total concentration can signal declining binding capacity or protein displacement. Falling free fraction can suggest increasing acute-phase proteins for certain basic compounds. Serial assessment can improve therapeutic precision, especially in unstable patients where one-time snapshots are less reliable.
Practical rule: if a drug is highly protein-bound and the patient has a major change in albumin, AAG, renal function, or inflammatory burden, verify free exposure instead of relying solely on total concentration.
Authoritative references for deeper study
- U.S. Food and Drug Administration (FDA): Clinical Pharmacology
- National Center for Biotechnology Information (NCBI, NIH): Principles of Pharmacokinetics
- NCBI/NIH: Therapeutic Drug Monitoring and Interpretation
In summary, free fraction calculation in plasma converts concentration data into actionable pharmacologic insight. The arithmetic is simple, but interpretation is clinical. When used thoughtfully, free fraction metrics improve dose decisions, toxicity prevention, and treatment precision in both routine care and advanced pharmacology practice.